BR112019012355A2 - derivados de pirazol como inibidores de malt1 - Google Patents
derivados de pirazol como inibidores de malt1 Download PDFInfo
- Publication number
- BR112019012355A2 BR112019012355A2 BR112019012355A BR112019012355A BR112019012355A2 BR 112019012355 A2 BR112019012355 A2 BR 112019012355A2 BR 112019012355 A BR112019012355 A BR 112019012355A BR 112019012355 A BR112019012355 A BR 112019012355A BR 112019012355 A2 BR112019012355 A2 BR 112019012355A2
- Authority
- BR
- Brazil
- Prior art keywords
- carboxamide
- trifluoromethyl
- pyridin
- pyrazol
- triazol
- Prior art date
Links
- 0 CNC(N1C=NC#CC1)=* Chemical compound CNC(N1C=NC#CC1)=* 0.000 description 47
- JZZNATMZUOQOAB-DGWRTRROSA-N C/C=C/C=N\N(c(ncc(NC(c1c[nH]nc1)=C)c1)c1Cl)N Chemical compound C/C=C/C=N\N(c(ncc(NC(c1c[nH]nc1)=C)c1)c1Cl)N JZZNATMZUOQOAB-DGWRTRROSA-N 0.000 description 1
- HBCNMOBDQWYUGF-BUHFOSPRSA-N CC(C)(/C(/NC)=C(/C=[IH])\C(Nc1ccc(C)c(C)c1)=N)F Chemical compound CC(C)(/C(/NC)=C(/C=[IH])\C(Nc1ccc(C)c(C)c1)=N)F HBCNMOBDQWYUGF-BUHFOSPRSA-N 0.000 description 1
- DKCCJBFZWZISEV-JZKRRNGWSA-N CC(Cc1c[N]([C@H](C)CCF)(C2=CCC=C=Cc3c2cccc3)nc1)/C=C/C Chemical compound CC(Cc1c[N]([C@H](C)CCF)(C2=CCC=C=Cc3c2cccc3)nc1)/C=C/C DKCCJBFZWZISEV-JZKRRNGWSA-N 0.000 description 1
- DXXGBKPVBFLBNY-ICKWWWFUSA-N CC(c1c(C(F)(F)F)[n](-c2cccc3c2C=CNC3=C)nc1)Nc(cc1Cl)c(C)nc1N/N=C\C(C)=N Chemical compound CC(c1c(C(F)(F)F)[n](-c2cccc3c2C=CNC3=C)nc1)Nc(cc1Cl)c(C)nc1N/N=C\C(C)=N DXXGBKPVBFLBNY-ICKWWWFUSA-N 0.000 description 1
- DFMRCWFTFPHCDR-UHFFFAOYSA-N CC1C=Cc2ncc(NN)[n]2C1 Chemical compound CC1C=Cc2ncc(NN)[n]2C1 DFMRCWFTFPHCDR-UHFFFAOYSA-N 0.000 description 1
- IUCPCAOAIGAJPJ-UHFFFAOYSA-N CCOc(c1ccccc11)ncc1-[n]1ncc(C(Nc2cc(Cl)c(-[n]3nccn3)nc2)=O)c1C(C)(F)F Chemical compound CCOc(c1ccccc11)ncc1-[n]1ncc(C(Nc2cc(Cl)c(-[n]3nccn3)nc2)=O)c1C(C)(F)F IUCPCAOAIGAJPJ-UHFFFAOYSA-N 0.000 description 1
- NQRYYUOFHJSTDK-UHFFFAOYSA-N Cc([n](-c1c(cccn2)c2ccc1)nc1)c1C(O)=O Chemical compound Cc([n](-c1c(cccn2)c2ccc1)nc1)c1C(O)=O NQRYYUOFHJSTDK-UHFFFAOYSA-N 0.000 description 1
- FZOVVOCXPHLGBJ-UHFFFAOYSA-O Cc1c(cccc2N[NH3+])c2cnc1 Chemical compound Cc1c(cccc2N[NH3+])c2cnc1 FZOVVOCXPHLGBJ-UHFFFAOYSA-O 0.000 description 1
- KOKAXRZWESADJT-UHFFFAOYSA-N Cc1cc(NC(c2c(C(F)(F)F)[n](-c3cccc4c3cccn4)nc2)=N)ccc1N Chemical compound Cc1cc(NC(c2c(C(F)(F)F)[n](-c3cccc4c3cccn4)nc2)=N)ccc1N KOKAXRZWESADJT-UHFFFAOYSA-N 0.000 description 1
- YFSMYPDRRLSNTH-UHFFFAOYSA-N Cc1cccc2ncc[n]12 Chemical compound Cc1cccc2ncc[n]12 YFSMYPDRRLSNTH-UHFFFAOYSA-N 0.000 description 1
- FMJUZBQZOHTOFR-UHFFFAOYSA-N Oc(c1c2cccc1)ncc2-[n]1ncc(C(Nc2cc(Cl)c(-[n]3nccn3)nc2)=O)c1C(F)(F)F Chemical compound Oc(c1c2cccc1)ncc2-[n]1ncc(C(Nc2cc(Cl)c(-[n]3nccn3)nc2)=O)c1C(F)(F)F FMJUZBQZOHTOFR-UHFFFAOYSA-N 0.000 description 1
- WHYQMULYJRVBCM-UHFFFAOYSA-N [O-][N+](c(cc1Cl)ccc1-[n]1nccn1)=O Chemical compound [O-][N+](c(cc1Cl)ccc1-[n]1nccn1)=O WHYQMULYJRVBCM-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662437384P | 2016-12-21 | 2016-12-21 | |
| PCT/US2017/067516 WO2018119036A1 (en) | 2016-12-21 | 2017-12-20 | Pyrazole derivatives as malt1 inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112019012355A2 true BR112019012355A2 (pt) | 2019-11-26 |
Family
ID=61628454
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112019012355A BR112019012355A2 (pt) | 2016-12-21 | 2017-12-20 | derivados de pirazol como inibidores de malt1 |
Country Status (23)
| Country | Link |
|---|---|
| US (2) | US10954214B2 (https=) |
| EP (1) | EP3558969B1 (https=) |
| JP (1) | JP7138641B2 (https=) |
| KR (1) | KR102583317B1 (https=) |
| CN (1) | CN110214136A (https=) |
| AR (1) | AR110421A1 (https=) |
| AU (2) | AU2017382185C1 (https=) |
| BR (1) | BR112019012355A2 (https=) |
| CA (1) | CA3048027A1 (https=) |
| CL (1) | CL2019001709A1 (https=) |
| CO (1) | CO2019006622A2 (https=) |
| EA (1) | EA201991503A1 (https=) |
| ES (1) | ES2992411T3 (https=) |
| IL (1) | IL267343B2 (https=) |
| MA (1) | MA47125A (https=) |
| MX (2) | MX392673B (https=) |
| PE (1) | PE20191755A1 (https=) |
| PH (1) | PH12019501212A1 (https=) |
| TN (1) | TN2019000192A1 (https=) |
| TW (1) | TWI795381B (https=) |
| UA (1) | UA127920C2 (https=) |
| UY (1) | UY37537A (https=) |
| WO (1) | WO2018119036A1 (https=) |
Families Citing this family (68)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3365340B1 (en) | 2015-10-19 | 2022-08-10 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| US20170145025A1 (en) | 2015-11-19 | 2017-05-25 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| ES2916874T3 (es) | 2015-12-17 | 2022-07-06 | Incyte Corp | Derivados de N-fenil-piridina-2-carboxamida y su uso como moduladores de la interacción proteína/proteína PD-1/PD-L1 |
| AU2016379372A1 (en) | 2015-12-22 | 2018-08-02 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| ES2906460T3 (es) | 2016-05-06 | 2022-04-18 | Incyte Corp | Compuestos heterocíclicos como inmunomoduladores |
| ES2905980T3 (es) | 2016-05-26 | 2022-04-12 | Incyte Corp | Compuestos heterocíclicos como inmunomoduladores |
| BR112018076534A2 (pt) | 2016-06-20 | 2019-04-02 | Incyte Corporation | compostos heterocíclicos como imunomoduladores |
| MA45669A (fr) | 2016-07-14 | 2019-05-22 | Incyte Corp | Composés hétérocycliques utilisés comme immunomodulateurs |
| ES2941716T3 (es) | 2016-08-29 | 2023-05-25 | Incyte Corp | Compuestos heterocíclicos como inmunomoduladores |
| TWI795381B (zh) | 2016-12-21 | 2023-03-11 | 比利時商健生藥品公司 | 作為ｍａｌｔ１抑制劑之吡唑衍生物 |
| ES2874756T3 (es) | 2016-12-22 | 2021-11-05 | Incyte Corp | Derivados de triazolo[1,5-A]piridina como inmunomoduladores |
| AU2017382870B2 (en) | 2016-12-22 | 2022-03-24 | Incyte Corporation | Benzooxazole derivatives as immunomodulators |
| ES2899402T3 (es) | 2016-12-22 | 2022-03-11 | Incyte Corp | Derivados de piridina como inmunomoduladores |
| WO2018119286A1 (en) | 2016-12-22 | 2018-06-28 | Incyte Corporation | Bicyclic heteroaromatic compounds as immunomodulators |
| MX2020003242A (es) | 2017-09-22 | 2020-09-18 | Jubilant Epipad LLC | Compuestos heterociclicos como inhibidores de pad. |
| AU2018352142B2 (en) | 2017-10-18 | 2022-08-25 | Jubilant Epipad LLC | Imidazo-pyridine compounds as PAD inhibitors |
| KR20200085836A (ko) | 2017-11-06 | 2020-07-15 | 주빌런트 프로델 엘엘씨 | Pd1/pd-l1 활성화 억제제로서의 피리미딘 유도체 |
| BR112020010322A2 (pt) | 2017-11-24 | 2020-11-17 | Jubilant Episcribe Llc | composto da fórmula i; composto da fórmula ia; composto da fórmula ib; processo de preparação de compostos da fórmula i; composição farmacêutica; método para o tratamento e/ou prevenção de várias doenças; uso dos compostos; método para o tratamento de câncer; e método para o tratamento e/ou prevenção de uma afecção mediada por prmt5 ou um distúrbio proliferativo ou câncer |
| MX2020006808A (es) | 2017-12-28 | 2020-12-11 | Massachusetts Gen Hospital | Ubicar al complejo de signalosoma cbm induce a las celulas t reguladoras inflamar al microambiente tumoral. |
| SG11202008950PA (en) | 2018-03-13 | 2020-10-29 | Jubilant Prodel LLC | Bicyclic compounds as inhibitors of pd1/pd-l1 interaction/activation |
| CR20200520A (es) | 2018-03-30 | 2021-03-09 | Incyte Corp | Compuestos heterocíclicos como inmunomoduladores |
| WO2019217821A1 (en) | 2018-05-11 | 2019-11-14 | Incyte Corporation | Tetrahydro-imidazo[4,5-c]pyridine derivatives as pd-l1 immunomodulators |
| ES2992431T3 (es) * | 2018-06-18 | 2024-12-12 | Janssen Pharmaceutica Nv | Derivados de pirazol como inhibidores de MALT1 |
| WO2019243964A1 (en) | 2018-06-18 | 2019-12-26 | Janssen Pharmaceutica Nv | Pyrazole derivatives as malt1 inhibitors |
| TW202045008A (zh) * | 2019-02-01 | 2020-12-16 | 印度商皮埃企業有限公司 | 4-取代的異噁唑/異噁唑啉(雜)芳基脒化合物、及其製備與用途 |
| JP2022523371A (ja) * | 2019-02-22 | 2022-04-22 | ヤンセン ファーマシューティカ エヌ．ベー． | 医薬製剤 |
| PH12021552018A1 (en) | 2019-02-22 | 2022-09-19 | Janssen Pharmaceutica Nv | Crystalline form of 1-(1-oxo-1,2-dihydroisoquinolin-5-yl)-5-(trifluoromethyl)-n-(2-(trifluoromethyl)pyridin-4-yl)-1h-pyrazole-4-carboxamide monohydrate |
| ES2949871T3 (es) | 2019-04-11 | 2023-10-03 | Janssen Pharmaceutica Nv | Anillos de piridina que contienen derivados como inhibidores de MALT1 |
| EP4010342A1 (en) | 2019-08-09 | 2022-06-15 | Incyte Corporation | Salts of a pd-1/pd-l1 inhibitor |
| WO2021067217A1 (en) | 2019-09-30 | 2021-04-08 | Incyte Corporation | Pyrido[3,2-d]pyrimidine compounds as immunomodulators |
| EP4048659A4 (en) * | 2019-10-24 | 2023-11-29 | ONO Pharmaceutical Co., Ltd. | Modulators of trek (twik related k+ channels) channel function |
| WO2021087086A1 (en) | 2019-10-30 | 2021-05-06 | Biogen Ma Inc. | Condensed pyridazine or pyrimidine as btk inhibitors |
| BR112022009031A2 (pt) | 2019-11-11 | 2022-10-11 | Incyte Corp | Sais e formas cristalinas de um inibidor de pd-1/pd-l1 |
| AU2020385647A1 (en) | 2019-11-22 | 2022-07-14 | Janssen Pharmaceutica Nv | Methods for assessing efficacy of MALT1 inhibitors using an NF-kB translocation assay |
| CN114981453A (zh) * | 2019-11-22 | 2022-08-30 | 詹森药业有限公司 | 用于评估malt1抑制剂的功效的nf-kb调节的基因表达测定 |
| WO2021138298A1 (en) * | 2019-12-30 | 2021-07-08 | Rheos Medicines, Inc. | Malt1 modulators and uses thereof |
| WO2021262969A1 (en) | 2020-06-24 | 2021-12-30 | The General Hospital Corporation | Materials and methods of treating cancer |
| JP2023539729A (ja) * | 2020-08-21 | 2023-09-19 | ヤンセン ファーマシューティカ エヌ．ベー． | Ｍａｌｔ１阻害剤の非晶質形態及びその製剤 |
| JP2023538099A (ja) | 2020-08-21 | 2023-09-06 | ヤンセン ファーマシューティカ エヌ．ベー． | Ｍａｌｔ１阻害剤と、ポリエチレングリコールの脂肪酸との混合物と、を含む、医薬製剤 |
| AU2021361057A1 (en) * | 2020-10-16 | 2023-06-08 | Rarefied Biosciences, Inc. | Malt1 modulators and uses thereof |
| US11780836B2 (en) | 2020-11-06 | 2023-10-10 | Incyte Corporation | Process of preparing a PD-1/PD-L1 inhibitor |
| US11866434B2 (en) | 2020-11-06 | 2024-01-09 | Incyte Corporation | Process for making a PD-1/PD-L1 inhibitor and salts and crystalline forms thereof |
| WO2022099075A1 (en) | 2020-11-06 | 2022-05-12 | Incyte Corporation | Crystalline form of a pd-1/pd-l1 inhibitor |
| US20230414629A1 (en) * | 2020-11-12 | 2023-12-28 | Monopteros Therapeutics, Inc. | Materials and methods of treating cancer |
| GB202018412D0 (en) * | 2020-11-23 | 2021-01-06 | Exscientia Ltd | Malt-1 modulators ii |
| WO2022167962A1 (en) * | 2021-02-04 | 2022-08-11 | Aurigene Discovery Technologies Limited | Substituted pyrazolyl compounds as malt-1 inhibitors |
| EP4301365A1 (en) | 2021-03-03 | 2024-01-10 | Janssen Pharmaceutica NV | Combination therapy using a malt1 inhibitor and a btk inhibitor |
| JP2024508890A (ja) | 2021-03-03 | 2024-02-28 | ヤンセン ファーマシューティカ エヌ．ベー． | 治療有効用量のｍａｌｔ１阻害剤ｊｎｊ－６７８５６６３３（１－（１－オキソ－１，２－ジヒドロイソキノリン－５－イル）－５－（トリフルオロメチル）－ｎ－（２－（トリフルオロメチル）ピリジン－４－イル）－１ｈ－ピラゾール－４－カルボキサミド）を使用して状態を治療する方法 |
| CN117120427A (zh) * | 2021-06-18 | 2023-11-24 | 上海拓界生物医药科技有限公司 | 一种malt1抑制剂及其制备方法和用途 |
| WO2023279986A1 (zh) * | 2021-07-05 | 2023-01-12 | 贝达药业股份有限公司 | 六元芳基或杂芳基酰胺类化合物及其组合物和用途 |
| KR20240046170A (ko) | 2021-08-09 | 2024-04-08 | 얀센 파마슈티카 엔브이 | B-세포 악성종양의 치료에 사용하기 위한 조성물 |
| CN113912511B (zh) * | 2021-11-29 | 2024-02-13 | 广东广康生化科技股份有限公司 | 一种联苯肼酯中间体的合成方法 |
| WO2023125877A1 (zh) | 2021-12-30 | 2023-07-06 | 上海翰森生物医药科技有限公司 | 三并环类衍生物抑制剂、其制备方法和应用 |
| EP4473966A4 (en) | 2022-02-02 | 2026-01-21 | Ono Pharmaceutical Co | CANCER TREATMENT AGENT COMPRISING A MALT1 INHIBITOR DRUG AS THE ACTIVE INGREDIENT |
| WO2023148501A1 (en) * | 2022-02-03 | 2023-08-10 | C4X Discovery Limited | Heterocyclic derivatives as malt1 inhibitors |
| TW202430514A (zh) | 2022-09-30 | 2024-08-01 | 瑞士商先正達農作物保護股份公司 | 殺微生物之吡唑衍生物 |
| TW202430031A (zh) | 2022-09-30 | 2024-08-01 | 瑞士商先正達農作物保護股份公司 | 殺微生物之吡唑衍生物 |
| EP4626882A1 (en) | 2022-11-30 | 2025-10-08 | Syngenta Crop Protection AG | Microbiocidal tetrahydroisoquinoline derivatives |
| WO2024125628A1 (zh) * | 2022-12-16 | 2024-06-20 | 江苏恒瑞医药股份有限公司 | 一种Malt 1抑制剂的磷酸酯前药 |
| TW202515873A (zh) * | 2023-06-29 | 2025-04-16 | 大陸商上海翰森生物醫藥科技有限公司 | 一種三并環類衍生物抑制劑的晶型及其製備方法 |
| WO2025002340A1 (zh) * | 2023-06-29 | 2025-01-02 | 上海翰森生物医药科技有限公司 | 三并环类抑制剂与抗癌剂在制备抗肿瘤药物中的联合应用 |
| WO2025069270A1 (ja) * | 2023-09-27 | 2025-04-03 | 日本新薬株式会社 | アザインドール化合物及び医薬 |
| AU2024357109A1 (en) | 2023-10-06 | 2026-03-12 | Ionctura Sa | Combination of roginolisib with a malt1-gls inhibitor |
| WO2025114167A1 (en) | 2023-11-28 | 2025-06-05 | Syngenta Crop Protection Ag | Microbiocidal pyrazole derivatives |
| WO2025174889A1 (en) * | 2024-02-13 | 2025-08-21 | Board Of Regents, The University Of Texas System | Malt1 and btk dual inhibitors |
| WO2025191053A1 (en) | 2024-03-14 | 2025-09-18 | Syngenta Crop Protection Ag | Microbiocidal pyrazole derivatives |
| WO2025210096A1 (en) | 2024-04-03 | 2025-10-09 | Syngenta Crop Protection Ag | Fungicidal compositions |
| WO2025210095A1 (en) | 2024-04-03 | 2025-10-09 | Syngenta Crop Protection Ag | Microbiocidal tetrahydroisoquinoline compounds |
Family Cites Families (71)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6339099B1 (en) | 1997-06-20 | 2002-01-15 | Dupont Pharmaceuticals Company | Guanidine mimics as factor Xa inhibitors |
| GB9721964D0 (en) * | 1997-10-16 | 1997-12-17 | Pfizer Ltd | Isoquinolines |
| DK173431B1 (da) | 1998-03-20 | 2000-10-23 | Gea Farmaceutisk Fabrik As | Farmaceutisk formulering omfattende en 2-[[(2-pyridinyl)methyl]sulfinyl]benzimidazol med anti-ulcusaktivitet samt fremgangs |
| FR2795726A1 (fr) | 1999-06-30 | 2001-01-05 | Aventis Cropscience Sa | Nouveaux pyrazoles fongicides |
| GB9925127D0 (en) | 1999-10-22 | 1999-12-22 | Pharmacia & Upjohn Spa | Oral formulations for anti-tumor compounds |
| AU2002363250A1 (en) | 2001-11-01 | 2003-05-12 | Icagen, Inc. | Pyrazole-amides and-sulfonamides |
| CA2522994C (en) * | 2003-04-30 | 2012-09-25 | Agensys, Inc. | Nucleic acids and corresponding proteins entitled 109p1d4 useful in treatment and detection of cancer |
| DK1618092T3 (da) | 2003-05-01 | 2011-01-31 | Bristol Myers Squibb Co | Aryl-substituerede pyrazol-amidforbindelser, der er anvendelige som kinasehæmmere |
| WO2006085685A1 (ja) | 2005-02-09 | 2006-08-17 | Takeda Pharmaceutical Company Limited | ピラゾール化合物 |
| CN100526430C (zh) | 2005-10-19 | 2009-08-12 | 中国石油化工股份有限公司 | 一种生产清洁汽油的方法 |
| TW200738682A (en) * | 2005-12-08 | 2007-10-16 | Organon Nv | Isoquinoline derivatives |
| ES2336625T3 (es) | 2006-03-22 | 2010-04-14 | Vertex Pharmaceuticals Incorporated | Inhibidores de la proteina quinasa c-met para el tratamiento de trastornos proliferativos. |
| WO2008008286A2 (en) | 2006-07-12 | 2008-01-17 | Merck & Co., Inc. | Substituted pyrazoles as ghrelin receptor antagonists |
| WO2008092292A1 (en) | 2007-01-17 | 2008-08-07 | The Hong Kong University Of Science And Technology | Isoquinolone compounds as subtype-selective agonists for melatonin receptors mt1 and mt2 |
| CN101652359A (zh) | 2007-03-09 | 2010-02-17 | 高点制药有限责任公司 | 作为羟类固醇脱氢酶抑制剂的吲哚-和苯并咪唑酰胺类 |
| CN101366715A (zh) | 2007-08-15 | 2009-02-18 | 上海医药工业研究院 | 一种雷帕霉素组合物及其制备方法 |
| US8309523B2 (en) | 2007-11-21 | 2012-11-13 | Vib Vzw | Inhibitors of MALT1 proteolytic activity and uses thereof |
| PL2342196T3 (pl) | 2008-09-24 | 2015-12-31 | Basf Se | Związki pirazolowe do zwalczania szkodników będących bezkręgowcami |
| WO2010039039A1 (en) | 2008-10-03 | 2010-04-08 | Clavis Pharma Asa | Oral formulations of gemcitabine derivatives |
| KR101061599B1 (ko) | 2008-12-05 | 2011-09-02 | 한국과학기술연구원 | 비정상 세포 성장 질환의 치료를 위한 단백질 키나아제 저해제인 신규 인다졸 유도체, 이의 약학적으로 허용가능한염 및 이를 유효성분으로 함유하는 약학적 조성물 |
| DE102009003954A1 (de) | 2009-01-07 | 2010-07-08 | Merck Patent Gmbh | Pyridazinonderivate |
| US8252821B2 (en) | 2009-04-14 | 2012-08-28 | Bristol-Myers Squibb Company | Bioavailable capsule compositions of amorphous alpha-(N-sulfonamido)acetamide compound |
| WO2011036885A1 (ja) | 2009-09-25 | 2011-03-31 | 武田薬品工業株式会社 | 複素環化合物 |
| US20120071497A1 (en) | 2010-06-03 | 2012-03-22 | Pharmacyclics, Inc. | Methods of treating abc-dlbcl using inhibitors of bruton's tyrosine kinase |
| CN107898791A (zh) | 2010-06-03 | 2018-04-13 | 药品循环有限责任公司 | 布鲁顿酪氨酸激酶(btk)抑制剂的应用 |
| JP5984801B2 (ja) | 2010-06-22 | 2016-09-06 | ビーエーエスエフ ソシエタス・ヨーロピアＢａｓｆ Ｓｅ | ４−ヒドロキシピリジン類の製造方法 |
| JP2013530199A (ja) | 2010-07-06 | 2013-07-25 | ノバルティス アーゲー | キナーゼ阻害剤として有用な環状エーテル化合物 |
| WO2012063896A1 (ja) | 2010-11-11 | 2012-05-18 | 第一三共株式会社 | 新規ピラゾールアミド誘導体 |
| KR20150020228A (ko) | 2012-05-31 | 2015-02-25 | 에프. 호프만-라 로슈 아게 | 아미노퀴나졸린 및 피리도피리미딘 유도체 |
| US20150225373A1 (en) | 2012-08-29 | 2015-08-13 | Respivert Limited | Kinase inhibitors |
| BR112015010504A2 (pt) | 2012-11-09 | 2017-12-05 | Univ Cornell | uso de inibidores de molécula pequena de malt1, método de identificação de um modulador de molécula pequena de malt1, e composição farmacêutica |
| WO2014086478A1 (en) | 2012-12-03 | 2014-06-12 | Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) | Inhibitors of malt1 protease |
| JP2016508152A (ja) | 2013-01-10 | 2016-03-17 | グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング | Ｃｒａｃチャネル阻害薬としての、ピラゾリルをベースとするカルボキサミド類ｉ |
| JP2015096499A (ja) * | 2013-10-11 | 2015-05-21 | 田辺三菱製薬株式会社 | 医薬組成物 |
| ES2738695T3 (es) * | 2014-05-28 | 2020-01-24 | Novartis Ag | Nuevos Derivados de Pirazolo Pirimidina y su uso como inhibidores de MALT1 |
| WO2015192081A1 (en) | 2014-06-13 | 2015-12-17 | Byrd, John C. | Biomarker for predicting response of cll to treatment with a btk inhibitor |
| WO2016005994A2 (en) | 2014-07-06 | 2016-01-14 | Gattefosse India Pvt. Ltd. | Pharmaceutical composition comprising solid dispersion of bcs class ii drugs with gelucires |
| CA2956550A1 (en) | 2014-08-08 | 2016-02-11 | Pharmacyclics Llc | Bruton's tyrosine kinase inhibitor combinations and uses thereof |
| EA032030B1 (ru) | 2014-09-10 | 2019-03-29 | Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед | Соединения в качестве ингибиторов реаранжированной во время трансфекции (ret) киназы |
| CN107205993B (zh) | 2014-12-06 | 2021-03-09 | 细胞内治疗公司 | 有机化合物 |
| WO2016209688A1 (en) | 2015-06-24 | 2016-12-29 | University Of Florida Research Foundation, Incorporated | Compositions for the treatment of cancer and uses thereof |
| RS63359B1 (sr) | 2015-11-06 | 2022-07-29 | Incyte Corp | Heterociklična jedinjenja kao inhibitori pi3k-gama |
| WO2017081641A1 (en) | 2015-11-13 | 2017-05-18 | Novartis Ag | Novel pyrazolo pyrimidine derivatives |
| JO3794B1 (ar) | 2015-12-10 | 2021-01-31 | Janssen Pharmaceutica Nv | المركبات متعددة الحلقات كمثبطات لتيروزين كيناز بروتون |
| CN107021963A (zh) | 2016-01-29 | 2017-08-08 | 北京诺诚健华医药科技有限公司 | 吡唑稠环类衍生物、其制备方法及其在治疗癌症、炎症和免疫性疾病上的应用 |
| US10882841B2 (en) | 2016-03-01 | 2021-01-05 | University Of Maryland, Baltimore | Wnt signaling pathway inhibitors for treatments of disease |
| WO2018020474A1 (en) | 2016-07-29 | 2018-02-01 | Lupin Limited | Substituted thiazolo-pyridine compounds as malt1 inhibitors |
| WO2018103060A1 (en) | 2016-12-09 | 2018-06-14 | Janssen Pharmaceutica Nv | Inhibitors of bruton's tyrosine kinase and methods of their use |
| ES2856248T3 (es) | 2016-12-21 | 2021-09-27 | Acerta Pharma Bv | Inhibidores de imidazopirazina de la tirosina quinasa de Bruton |
| JOP20190152A1 (ar) | 2016-12-21 | 2019-06-20 | Novartis Ag | مضادات الميوستاتين، الآكتيفين أو مستقبلات الآكتيفين للاستخدام في علاج السمنة والحالات ذات الصلة |
| JOP20190148A1 (ar) | 2016-12-21 | 2019-06-18 | Bayer Pharma AG | أشكال جرعات صيدلية تحتوي على مثبطات قنوات task-1 و task-3 واستخدامها لمعالجة الاضطرابات التنفسية |
| JOP20190141A1 (ar) | 2016-12-21 | 2019-06-12 | Bayer Pharma AG | أشكال جرعات صيدلية تحتوي على مثبطات لقناة task-1 و task-3 واستخدامها في معالجة اضطراب تنفسي |
| TWI795381B (zh) | 2016-12-21 | 2023-03-11 | 比利時商健生藥品公司 | 作為ｍａｌｔ１抑制劑之吡唑衍生物 |
| LT3478719T (lt) | 2016-12-21 | 2021-04-12 | Mereo Biopharma 3 Limited | Antisklerostinų antikūnų naudojimas gydant osteogenesis imperfecta |
| US20200009135A1 (en) | 2017-02-01 | 2020-01-09 | Medivir Ab | Therapeutic applications of malt1 inhibitors |
| WO2018165385A1 (en) | 2017-03-08 | 2018-09-13 | Cornell University | Inhibitors of malt1 and uses thereof |
| WO2018226150A1 (en) | 2017-06-05 | 2018-12-13 | Medivir Aktiebolag | Pyrazolopyrimidine as malt-1 inhibitors |
| MX2020006808A (es) | 2017-12-28 | 2020-12-11 | Massachusetts Gen Hospital | Ubicar al complejo de signalosoma cbm induce a las celulas t reguladoras inflamar al microambiente tumoral. |
| US20210001733A1 (en) | 2018-02-23 | 2021-01-07 | Industrieanlagen-Betriebsgesellschaft Mbh | Device for generating a magnetic field, in particular for an inductive charging system, and primary device of an inductive charging system for dynamically charging vehicles |
| ES2992431T3 (es) | 2018-06-18 | 2024-12-12 | Janssen Pharmaceutica Nv | Derivados de pirazol como inhibidores de MALT1 |
| WO2019243964A1 (en) | 2018-06-18 | 2019-12-26 | Janssen Pharmaceutica Nv | Pyrazole derivatives as malt1 inhibitors |
| JP2022523371A (ja) | 2019-02-22 | 2022-04-22 | ヤンセン ファーマシューティカ エヌ．ベー． | 医薬製剤 |
| PH12021552018A1 (en) | 2019-02-22 | 2022-09-19 | Janssen Pharmaceutica Nv | Crystalline form of 1-(1-oxo-1,2-dihydroisoquinolin-5-yl)-5-(trifluoromethyl)-n-(2-(trifluoromethyl)pyridin-4-yl)-1h-pyrazole-4-carboxamide monohydrate |
| ES2949871T3 (es) | 2019-04-11 | 2023-10-03 | Janssen Pharmaceutica Nv | Anillos de piridina que contienen derivados como inhibidores de MALT1 |
| AU2020385647A1 (en) | 2019-11-22 | 2022-07-14 | Janssen Pharmaceutica Nv | Methods for assessing efficacy of MALT1 inhibitors using an NF-kB translocation assay |
| CN114981453A (zh) | 2019-11-22 | 2022-08-30 | 詹森药业有限公司 | 用于评估malt1抑制剂的功效的nf-kb调节的基因表达测定 |
| WO2021138298A1 (en) | 2019-12-30 | 2021-07-08 | Rheos Medicines, Inc. | Malt1 modulators and uses thereof |
| JP2023539729A (ja) | 2020-08-21 | 2023-09-19 | ヤンセン ファーマシューティカ エヌ．ベー． | Ｍａｌｔ１阻害剤の非晶質形態及びその製剤 |
| JP2023538099A (ja) | 2020-08-21 | 2023-09-06 | ヤンセン ファーマシューティカ エヌ．ベー． | Ｍａｌｔ１阻害剤と、ポリエチレングリコールの脂肪酸との混合物と、を含む、医薬製剤 |
| EP4301365A1 (en) | 2021-03-03 | 2024-01-10 | Janssen Pharmaceutica NV | Combination therapy using a malt1 inhibitor and a btk inhibitor |
| JP2024508890A (ja) | 2021-03-03 | 2024-02-28 | ヤンセン ファーマシューティカ エヌ．ベー． | 治療有効用量のｍａｌｔ１阻害剤ｊｎｊ－６７８５６６３３（１－（１－オキソ－１，２－ジヒドロイソキノリン－５－イル）－５－（トリフルオロメチル）－ｎ－（２－（トリフルオロメチル）ピリジン－４－イル）－１ｈ－ピラゾール－４－カルボキサミド）を使用して状態を治療する方法 |
-
2017
- 2017-12-19 TW TW106144535A patent/TWI795381B/zh not_active IP Right Cessation
- 2017-12-20 WO PCT/US2017/067516 patent/WO2018119036A1/en not_active Ceased
- 2017-12-20 MA MA047125A patent/MA47125A/fr unknown
- 2017-12-20 PE PE2019001288A patent/PE20191755A1/es unknown
- 2017-12-20 MX MX2019007540A patent/MX392673B/es unknown
- 2017-12-20 US US15/847,999 patent/US10954214B2/en active Active
- 2017-12-20 CA CA3048027A patent/CA3048027A1/en active Pending
- 2017-12-20 EA EA201991503A patent/EA201991503A1/ru unknown
- 2017-12-20 CN CN201780079706.3A patent/CN110214136A/zh active Pending
- 2017-12-20 KR KR1020197021137A patent/KR102583317B1/ko active Active
- 2017-12-20 ES ES17851862T patent/ES2992411T3/es active Active
- 2017-12-20 JP JP2019533465A patent/JP7138641B2/ja active Active
- 2017-12-20 BR BR112019012355A patent/BR112019012355A2/pt not_active Application Discontinuation
- 2017-12-20 UA UAA201908268A patent/UA127920C2/uk unknown
- 2017-12-20 EP EP17851862.7A patent/EP3558969B1/en active Active
- 2017-12-20 AU AU2017382185A patent/AU2017382185C1/en active Active
- 2017-12-20 TN TNP/2019/000192A patent/TN2019000192A1/en unknown
- 2017-12-21 AR ARP170103626A patent/AR110421A1/es not_active Application Discontinuation
- 2017-12-21 UY UY0001037537A patent/UY37537A/es not_active Application Discontinuation
-
2019
- 2019-05-31 PH PH12019501212A patent/PH12019501212A1/en unknown
- 2019-06-13 IL IL267343A patent/IL267343B2/en unknown
- 2019-06-19 CL CL2019001709A patent/CL2019001709A1/es unknown
- 2019-06-21 MX MX2022005827A patent/MX2022005827A/es unknown
- 2019-06-21 CO CONC2019/0006622A patent/CO2019006622A2/es unknown
-
2020
- 2020-11-25 US US17/104,081 patent/US12077521B2/en active Active
-
2022
- 2022-02-28 AU AU2022201352A patent/AU2022201352A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2017382185C9 (en) | Pyrazole derivatives as MALT1 inhibitors | |
| US20230330099A1 (en) | Substituted indole mcl-1 inhibitors | |
| JP7296408B2 (ja) | Ｍａｌｔ１阻害剤としてのピラゾール誘導体 | |
| TWI878423B (zh) | 環狀化合物及其使用方法 | |
| JP2019504821A (ja) | ユビキチン特異的プロテアーゼ１阻害剤としてのプリノン | |
| TW201016676A (en) | Heterocyclic derivatives and methods of use thereof | |
| EA028626B1 (ru) | БЕНЗИМИДАЗОЛЫ, МОДУЛИРУЮЩИЕ TNF-α | |
| CA2857302A1 (en) | Use of inhibitors of the activity or function of pi3k | |
| WO2019089835A1 (en) | Diazanaphthalen-3-yl carboxamides and preparation and use thereof | |
| JP7357932B2 (ja) | Ｃｒｈｒ２拮抗薬としての縮合環状尿素誘導体 | |
| OA19506A (en) | Pyrazole derivatives as malt1 inhibitors. | |
| EA045333B1 (ru) | Производные пиразола в качестве ингибиторов malt1 | |
| OA20881A (en) | Pyrazole derivatives as MALT1 inhibitors. | |
| HK40014620A (en) | Pyrazole derivatives as malt1 inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] | ||
| B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B11B | Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements |